SAN DIEGO, February 15, 2017
SAN DIEGO, February 15, 2017 /PRNewswire/ --
Entest BioMedical Inc.'s (OTCPINK: ENTB) wholly owned subsidiary, Zander Therapeutics Inc., announced today publication by the United States Patent and Trademark Office of a Utility Patent application entitled "Canine Autologous Immunotherapy using Dendritic Cell Induced Cancer Killing Immunocytes". This patent application, which has a priority date of July 2015 and is assigned to Zander Therapeutics, covers the generation of a new type of cell from dog blood which possesses ability to kill tumor cells.
"Currently Zander Therapeutics is pursuing a highly targeted strategy of therapeutically modifying the immune system in cats, dogs and horses using small molecule modulators of NR2F6 activity. In this particular case, the current patent publication extends the intellectual property walls that Zander is establishing by covering specific means of generating immune system cells that can be modified by the small molecules in development," said Harry Lander, Ph.D., President and Chief Scientific Officer of Zander Therapeutics.
It is believed that the veterinary medical market is approximately $63 billion a year. The majority of veterinary conditions comprise either oncology or autoimmune/inflammatory diseases. Modulation of the immune system, either with small molecules or new ways of growing immune cells, can address both cancer (in which immune activation is desired) or autoimmunity/inflammation where regulation of pathological immune responses is sought.
"Since the initial filing of this patent application in 2015, major successes have been achieved in the human biotechnology space utilizing cellular therapies as a means of increasing immune response to cancers. One striking example of this field moving forward is the recent announcement by Novartis of 80% remissions in its recent cancer cell therapy clinical trial http://www.thepharmaletter.com/article/more-than-80-complete-remission-rate-in-novartis-car-t-therapy-trial. Another is KITE Pharma announcing filing with the FDA for marketing approval of its cellular therapy http://www.thepharmaletter.com/article/first-car-t-therapy-bla-filing-initiated-with-us-fda . We at Zander Therapeutics intend to accelerate the rate of our veterinary immunology research progress, the objective being to make available to animals advances in therapies comparable to what is being developed in the field of human medicine," noted David Koos, Chairman and CEO of Zander Therapeutics Inc.
About Zander Therapeutics Inc.:
Zander Therapeutics is a wholly owned subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.
Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (wholly owned by Entest BioMedical Inc.).
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Zander Therapeutics Inc. and Entest BioMedical Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
SOURCE Entest BioMedical Inc.